Should I buy Amgen stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking Amgen's performance for over three years. Every month, over a million users in the US trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes only and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Amgen.

What is Amgen?

How much is Amgen stock?

The price of Amgen stock is rising this week. Amgen is currently trading at $297.81, up 0.32% over the past 24 hours and showing a 6.70% gain for the week. The company has a market capitalization of $160.13 billion and averages 3.07 million shares traded daily. Its current P/E ratio stands at 27.12, with a dividend yield of 3.21% and a five-year beta of 0.50. Amgen’s balanced fundamentals and recent upward momentum provide investors with a compelling combination of stability and growth potential.

Our full analysis of Amgen stock

We have conducted an in-depth review of Amgen’s latest financial statements, benchmarked its stock performance over the past three years, and utilized our proprietary algorithms to synthesize insights from a wide range of analytical sources: financial ratios, technical momentum, market data, and cross-comparisons with sector competitors. This comprehensive approach is designed to identify actionable patterns and reveal robust market signals. So, why might Amgen stock once again become a strategic entry point into the life sciences and biotechnology sector in 2025?

Recent performance and market context

Amgen’s share price has displayed remarkable strength recently, closing at $297.81, up 6.7% for the week, and maintaining a 14% gain over the past six months. This momentum stands in stark contrast to the -3.7% annual dip, illustrating a strong recovery phase. The renewed investor interest can be attributed to a combination of outperforming Q1 earnings, robust product pipeline developments, and sector-wide optimism, particularly as major indices like the NASDAQ show renewed vigor. Macroeconomic drivers, including the resilience of US healthcare demand and increasing allocations to defensive growth stocks amid global uncertainty, have further contributed to an attractive setup for leading biopharma names like Amgen. Consensus analyst price targets, now set above $314, reinforce the conviction that Amgen is poised for continued upside.

Technical analysis

Technical indicators support an increasingly bullish structure. The Relative Strength Index (RSI) currently sits at 44.58, signaling a neutral yet potentially bullish stance as the stock recovers from oversold territory. MACD levels, now at 1.77, have moved into a clear buy zone—pointing to growing upward momentum. The 5-day moving average of $287.40 has held as a dynamic support, while the 52-week absolute support at $253.30 has repeatedly attracted buyers, limiting downside risk. Resistance is well defined at $346.85, presenting an attainable target on further positive catalysts. Short-term technical targets are marked at $299 and $305, which, if surpassed, could establish a new base for the next bullish leg. Overall, Amgen’s chart pattern suggests the formation of a sustained recovery, further validated by recent high-volume upswings and leading short-term averages turning positive.

Fundamental analysis

Amgen’s fundamentals are solid and strengthening. Q1 2025 revenues reached $8.1 billion, up 9% year-on-year, propelled by double-digit sales growth in core therapeutics. Non-GAAP EPS soared to $4.90 (+24% YoY), reflecting operational leverage and disciplined cost management. The company guides for full-year revenues between $34.3 and $35.7 billion, projecting GAAP and non-GAAP profitability at multi-year highs. With a trailing P/E ratio of 27.1 and a forward P/E of 14.2, Amgen’s valuation becomes especially attractive when placed against historical averages and sector peers. Its annual dividend yield of 3.21% further enhances shareholder returns, supported by a well-established capital return policy and the potential for future hikes. The diversified product mix—spanning oncology, rare diseases, autoimmune, and general medicines—anchors ongoing growth, while $1.5 billion invested in R&D in Q1 alone underscores leadership in innovation. Notably, the rapid uptake of next-generation therapies such as Repatha, EVENITY, and TEZSPIRE, as well as ongoing pipeline expansion, confirm Amgen’s status as a future-ready biopharma titan.

Volume and liquidity

Average daily trading volume of 3.07 million shares has been consistently robust, reflecting strong institutional and retail interest. This liquidity profile eases market access for investors and signifies consensus confidence in Amgen’s future prospects. Its free float, sizable yet balanced, provides for both dynamic price discovery and efficient capital allocation—key for sustaining momentum during both bullish and corrective phases. The stock’s five-year beta stands at 0.50, denoting low market volatility and positioning Amgen as a relative safe haven within higher-risk equity portfolios.

Catalysts and positive outlook

• 혁신 pipeline: The lead candidate, MariTide, is now in Phase 3 trials for obesity—a rapidly expanding market where Amgen’s monthly dosing could challenge and potentially surpass current industry leaders.
• Regulatory milestones: Recent FDA approvals for novel therapies (IMDELLTRA, UPLIZNA) and validation of Rocatinlimab’s positive Phase 3 results reinforce regulatory credibility and open high-value markets.
• Geographic expansion: Major launches such as IMDELLTRA in Japan are expected to meaningfully boost revenues while diversifying regional exposure.
• ESG and sustainable practices: Amgen’s commitment to responsible growth, with transparent governance and clear sustainability goals, enhances its institutional appeal.
• Financial discipline: Aggressive share repurchases (up to $500 million authorized), stable dividend policy, and a solid balance sheet ensure the company can fund innovation and reward shareholders in tandem.

Investment strategies

Investors seeking short-term gains may find timely entry points on minor pullbacks above $287.40, with targets set on a breakout above $305 and towards the prior high at $346.85. For the medium term, the stock’s momentum—combined with ongoing pipeline news and quarterly earnings reports—favors accumulating on technical support zones or when bullish volume surges appear. Long-term investors, in turn, stand to benefit from Amgen’s strong dividend yield, best-in-class R&D, and expanding market leadership driven by innovative therapies poised to address major unmet medical needs. Positioning ahead of potential blockbuster drug launches (like MariTide), sector rotation into healthcare, or further analyst upgrades could yield significant rewards. The current price/earnings multiple relative to growth outlook, dividend sustainability, and sector tailwinds together frame an unusually attractive risk/reward profile for US and global investors alike.

Is it the right time to buy Amgen?

Amgen’s rare combination of technical strength, superior growth, and innovation-driven fundamentals justifies renewed, enthusiastic attention for 2025. Recent momentum, confirmed by both technical and fundamental signals, suggests that the stock may be entering a new bullish phase. Strong institutional activity, a best-in-class product pipeline, accelerating revenue and earnings growth, and an above-average yield provide a solid foundation for both near- and long-term outperformance. While every investment carries inherent risks, the balance of evidence undeniably supports the view that Amgen currently represents an excellent opportunity for investors seeking leadership, resilience, and growth in the biotechnology sector.

In this context, Amgen stands as a strategic entry point at the intersection of scientific innovation and robust financial performance—offering investors the kind of upside potential that only true sector leaders can provide.

How to buy Amgen stock in the United States?

Buying Amgen stock online is straightforward and secure when using a regulated US broker. You typically have two main options: you can purchase Amgen shares outright (“spot buying”) for direct ownership or use Contracts for Difference (CFDs) for leveraged trading. Each method has its advantages, and a detailed broker comparison is provided further down this page to help you find the right platform.

Spot buying

A cash purchase means you’re buying Amgen shares directly, which are then held in your brokerage account. Most US brokers charge a fixed fee per transaction—usually around $5—making it easy to track your costs.

Gain scenario for an Amgen share investment

If the Amgen share price is $297.81, you can buy around 3 shares with a $1,000 stake, including a brokerage fee of around $5.

Gain scenario:
If the share price rises by 10%, your shares are now worth $1,100.
Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

Trading Amgen shares as CFDs allows you to speculate on price movements without owning the underlying asset. Typical costs include the spread (the difference between buy and sell prices) and overnight financing fees if you keep leveraged positions open. CFDs give you the flexibility of leverage, but also increase your risk exposure.

CFD Gain Scenario

You open a CFD position on Amgen shares, with 5x leverage. This gives you a market exposure of $5,000.

Gain scenario: If the stock rises by 8%, your position gains 8% × 5 = 40%. Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Always compare brokers’ fees, trading conditions, and account features before investing. Whether you choose spot buying for long-term investing or CFDs for leveraged trading, your decision should reflect your investment goals and risk tolerance. For more details, explore the broker comparison lower on this page.

Our 7 Tips for Buying Amgen Stock

The latest news about Amgen

Amgen stock posted a notable 6.7% gain over the past week, reflecting renewed investor interest. This uptick coincided with market recognition of strong Q1 volume growth and positive product sales momentum, particularly relevant for US-based investors closely tracking Nasdaq healthcare leaders.

Amgen reports continued robust sales in key segments, led by double-digit growth in Repatha, EVENITY, TEZSPIRE, and BLINCYTO. Recent disclosures confirm that Q1 2025 revenue for these products all exceeded 25% year-over-year growth, signaling strong domestic demand and sustaining the company’s leadership position in US specialty biopharma.

Phase 3 clinical trials for MariTide, a novel obesity drug, advance in the US with high market potential. Following successful Phase 2 results, MariTide is positioned as a once-monthly alternative to existing treatments; American payers, clinicians, and patients are showing growing interest in this competitive innovation, which could impact long-term revenue streams.

Amgen’s forward-looking guidance for 2025 remains upbeat, projecting total revenue between $34.3 and $35.7 billion. This outlook, paired with forecasted non-GAAP EPS of $20.00–$21.20, highlights confidence in the US product mix, driving positive analyst consensus for the coming quarters.

US regulatory milestones and partnerships strengthen Amgen's national footprint and stock sentiment. Notably, the recent FDA approval for UPLIZNA in a new indication and the US rollout of multiple Phase 3 results underscore the company's capacity to navigate US healthcare regulations and reinforce its reputation among stateside institutional investors.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.